Resiquimod

Resiquimod

Systematic (IUPAC) name
1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
Clinical data
Routes of administration	Topical
Legal status	Investigational
Identifiers
CAS Number	144875-48-9
ATC code	none
PubChem	CID 159603
IUPHAR/BPS	5051
ChemSpider	140330
UNII	V3DMU7PVXF
ChEMBL	CHEMBL383322
Chemical data
Formula	C17H22N4O2
Molar mass	314.382 g/mol
SMILES CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
InChI InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19) Key:BXNMTOQRYBFHNZ-UHFFFAOYSA-N
(what is this?)  (verify)

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel^[1] in the treatment of skin lesions^[2] such as those caused by the herpes simplex virus^[3][4] and cutaneous T cell lymphoma,^[5] and as an adjuvant to increase the effectiveness of vaccines.^[6] It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8,^[7] and an upregulator of the opioid growth factor receptor.^[8]

See also

• Imiquimod
• Gardiquimod

References

1. Patents #5, 939, 090 and 6, 365, 166
2. Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC (July 2008). "A phase II dose-ranging study of topical resiquimod to treat actinic keratosis". The British Journal of Dermatology 159 (1): 205–10. doi:10.1111/j.1365-2133.2008.08615.x. PMID 18476957.
3. Wu JJ, Huang DB, Tyring SK (November 2004). "Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses". Antiviral Research 64 (2): 79–83. doi:10.1016/j.antiviral.2004.07.002. PMID 15498602.
4. Fife KH, Meng TC, Ferris DG, Liu P (February 2008). "Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions". Antimicrobial Agents and Chemotherapy 52 (2): 477–82. doi:10.1128/AAC.01173-07. PMC 2224757. PMID 18039918.
5. Rook AH, Gelfand JC, Wysocka M, Troxel AB, Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R, Kirsch I, Kim EJ, and Clark RA (July 30, 2015). "Topical resiquimod can induce disease regression, eradicate malignant T cells and enhance T cell effector functions in cutaneous T cell lymphoma". Blood (American Society of Hematology). doi:10.1182/blood-2015-02-630335.
6. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP (October 2007). "Resiquimod and other immune response modifiers as vaccine adjuvants". Expert Review of Vaccines 6 (5): 835–47. doi:10.1586/14760584.6.5.835. PMID 17931162.
7. Hurst J, Prinz N, Lorenz M, Bauer S, Chapman J, Lackner KJ, von Landenberg P (February 2009). "TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells". Immunobiology 214 (8): 683–91. doi:10.1016/j.imbio.2008.12.003. PMID 19249118.
8. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ (August 2008). "Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function". Experimental Biology and Medicine (Maywood, N.J.) 233 (8): 968–79. doi:10.3181/0802-RM-58. PMID 18480416.